301408SZSE
🚨 Material Event

Announcement on Wholly-Owned Subsidiary Receiving Drug Registration Certificate

✨ AI Summary

Anhui HuaRen Health Pharmaceutical Co., Ltd. announces its wholly-owned subsidiary, Jiangsu Shenhua Pharmaceutical Co., Ltd., has received a Drug Registration Certificate for Sacubitril Valsartan Sodium Tablets from the NMPA. This approval is expected to enrich the company's cardiovascular product line, enhance market competitiveness, and positively impact future operations and performance. The company will expedite production and sales, while acknowledging market uncertainties.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Stock Code: 301408 Stock Abbreviation: HuaRen Health Announcement No.: 2026-037

Anhui HuaRen Health Pharmaceutical Co., Ltd.

Announcement on Wholly-Owned Subsidiary Receiving Drug Registration Certificate

The Company and all members of the Board of Directors guarantee the content of this information disclosure is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.

Recently, Anhui HuaRen Health Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") wholly-owned subsidiary Jiangsu Shenhua Pharmaceutical Co., Ltd. received the approved and issued Drug Registration Certificate for Sacubitril Valsartan Sodium Tablets from the National Medical Products Administration (hereinafter referred to as the "NMPA"). The relevant situation is hereby announced as follows:

I. Basic Information of the Drug

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.